TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16893273

Group type: EXPERIMENTAL
Intervention: Contingency Management with Cognitive-Behavioral Therapy (CM+CBT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy alone (CBT)
Number of subjects: 28
Study: 12850963

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound device (QUS), Sahara clinical bone sonometer
Number of subjects: 267

Group type: COMPARATOR
Intervention: Dual energy X‐ray absorptiometry (DEXA)
Number of subjects: 267
Study: 10591815

Group type: EXPERIMENTAL
Intervention: Depressive patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 8910179

Group type: EXPERIMENTAL
Intervention: Manual ventilation initiated when SpO2 decreased to 90% (Subgroup A)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Manual ventilation initiated when SpO2 decreased to 95% (Subgroup B)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Age group 3-12 years (Group 3)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: All children
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 152
Study: 1922792

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nondrug conditions
Number of subjects: 21
Study: 6412157

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 19
Study: 4081473

Group type: EXPERIMENTAL
Intervention: Aztreonam treatment
Number of subjects: 112
Study: 29509642

Group type: EXPERIMENTAL
Intervention: GnRHAG + E2
Number of subjects: 61

Group type: COMPARATOR
Intervention: GnRHAG + PL
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GnRHAG + E2 (no structured exercise)
Number of subjects: 61

Group type: COMPARATOR
Intervention: GnRHAG + PL (no structured exercise)
Number of subjects: 61
Study: 29952487

Group type: EXPERIMENTAL
Intervention: Iodine supplemented group
Number of subjects: 266

Group type: COMPARATOR
Intervention: No‐iodine supplemented group
Number of subjects: 266
Study: 24196554

Group type: EXPERIMENTAL
Intervention: Structured coaching
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 17
Study: 22208450

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20471542

Group type: EXPERIMENTAL
Intervention: Evidence-based practices (EBPs) for pain management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain medication order
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Review of pain treatment plan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reassessment of moderate or greater pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in pain medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of analgesic-induced side effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of bowel regimen for patients with opioid order
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Documentation of nonpharmacological therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written pain management plans
Number of subjects: 0
Study: 17339120

Group type: EXPERIMENTAL
Intervention: Thought suppression under cognitive load
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concentration on the thought
Number of subjects: 0
Study: 15919489

Group type: COMPARATOR
Intervention: Tac/MMF
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Tac/0.5SIR
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Tac/2SIR
Number of subjects: 624
Study: 12752032

Group type: EXPERIMENTAL
Intervention: Hallucination focused Integrative Treatment (HIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study: 10333127

Group type: EXPERIMENTAL
Intervention: 4.2% sodium bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4.5% human albumin
Number of subjects: 0
Study: 8604439

Group type: EXPERIMENTAL
Intervention: Electrophysiologic study (EPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holter monitoring (HM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPS combined with HM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicted drug efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study: 1932651

Group type: EXPERIMENTAL
Intervention: Succinyl‐linked gelatin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Urea‐linked gelatin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 105
Study: 6218104

Group type: EXPERIMENTAL
Intervention: Mezlocillin (2 g intravenously before surgery and every eight hours until the fifth postoperative day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no mezlocillin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 100
Study: 31356571

Group type: EXPERIMENTAL
Intervention: Evidence-based pain management strategies implemented after the audit
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline audit before implementation
Number of subjects: 30
Study: 30016473

Group type: EXPERIMENTAL
Intervention: Behavioral health intervention
Number of subjects: 187

Group type: COMPARATOR
Intervention: Enhanced Usual PC (UC+)
Number of subjects: 187
Study: 26878838

Group type: EXPERIMENTAL
Intervention: Nurse-led multidisciplinary pulmonary rehabilitation programme (6-week duration)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Nurse-led multidisciplinary pulmonary rehabilitation programme
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 25193157

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 micrograms every 2 hours for a maximum of 12 doses or until active labor commences
Number of subjects: 602

Group type: COMPARATOR
Intervention: Transcervical Foley catheter (silicone, size 18 F with 30 ml balloon) until active labor starts, the Foley catheter falls out, or 12 hours have elapsed
Number of subjects: 602
Study: 22869830

Group type: EXPERIMENTAL
Intervention: Eucalyptus honey
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Citrus honey
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Labiatae honey
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (silan date extract)
Number of subjects: 300
Study: 19783324

Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard monitoring alone (blinded capnography)
Number of subjects: 132
Study: 17413103

Group type: EXPERIMENTAL
Intervention: 7 g fat/d (2.4 g fat/meal)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 15 g fat/d (5 g fat/meal)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 29 g fat/d (10 g fat/meal)
Number of subjects: 116
Study: 15621801

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² once a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-rituximab interventions (observation, immunosuppression reduction, surgery, chemotherapy, radiation or a combination)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Response to treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CD20 positive status
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low international prognostic index (IPI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Good performance status
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CD20-positive status
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low performance status
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low IPI and rituximab therapy
Number of subjects: 30
Study: 11172269

Group type: EXPERIMENTAL
Intervention: Pneumatic compression therapy delivered after elective hip surgery
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nursing education program
Number of subjects: 79
Study: 9692584

Group type: EXPERIMENTAL
Intervention: Open antireflux surgery
Number of subjects: 178
Study: 7842828

Group type: EXPERIMENTAL
Intervention: Teicoplanin plus netilmicin 5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teicoplanin plus pefloxacine 10 mg/kg
Number of subjects: 40
Study: 3136820

Group type: EXPERIMENTAL
Intervention: Trisdine instillations
Number of subjects: 18

Group type: COMPARATOR
Intervention: kanamycin-colistin instillations
Number of subjects: 18
Study: 31227453

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS) applied daily for 3 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no LIPUS treatment)
Number of subjects: 21
Study: 28304224

Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks or 420 mg monthly)
Number of subjects: 27564

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study: 25376374

Group type: EXPERIMENTAL
Intervention: Sibling RIC transplant
Number of subjects: 0

Group type: COMPARATOR
Intervention: MUD RIC transplant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients aged 35-44 years with sibling RIC transplant
Number of subjects: 0
Study: 23880306

Group type: EXPERIMENTAL
Intervention: Immediate ART initiation regardless of CD4 count
Number of subjects: 34000

Group type: COMPARATOR
Intervention: ART according to national treatment eligibility guidelines (CD4 <350 cells/μL, WHO stage 3 or 4 disease, or multidrug/extensively drug-resistant tuberculosis)
Number of subjects: 34000

Group type: COMPARATOR
Intervention: ART according to national treatment eligibility guidelines
Number of subjects: 34000
Study: 21714857

Group type: EXPERIMENTAL
Intervention: Fenoldopam (1 μg/kg/min continuous infusion during CPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (during CPB)
Number of subjects: 80
Study: 19379152

Group type: EXPERIMENTAL
Intervention: Lipoproten apheresis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 18349477

Group type: COMPARATOR
Intervention: Quota-based walking program (8-week duration)
Number of subjects: 3
Study: 15241887

Group type: EXPERIMENTAL
Intervention: Shampoo containing a standardized extract of Solanum chrysotrichum (applied every third day for 4 weeks)
Number of subjects: 103

Group type: COMPARATOR
Intervention: 2% ketoconazole
Number of subjects: 103
Study: 11263600

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7159

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 7159

Group type: EXPERIMENTAL
Intervention: Patients with 3-vessel disease (3VD) undergoing PCI
Number of subjects: 7159

Group type: EXPERIMENTAL
Intervention: Patients with 2-vessel disease (2VD) undergoing PCI
Number of subjects: 7159
Study: 9135945

Group type: EXPERIMENTAL
Intervention: Human insulin (0.05 IU/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin (correctly informed)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin (expectation without knowledge)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (expectation without knowledge)
Number of subjects: 40
Study: 7870881

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3777587

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given as a single dose one hour after SRT dosing (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given in four doses at three-hour intervals starting one hour after SRT dosing (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given in four doses at three-hour intervals starting three hours after SRT dosing (Group 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given in three doses at three-hour intervals starting six hours after SRT dosing (Group 4)
Number of subjects: 20
Study: 30987860

Group type: EXPERIMENTAL
Intervention: Cathodal ctDCS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Anodal ctDCS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 48
Study: 28757287

Group type: EXPERIMENTAL
Intervention: High-load lifting exercise (HLL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low-load motor control exercises (LMC)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Subgroup LOW lumbar lordosis (LOWlu)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Subgroup HIGH sacral angle (HIGHsa)
Number of subjects: 66
Study: 26689566

Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) 50 mg enteric-coated tablet under fed conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alisertib (MLN8237) 50 mg enteric-coated tablet under fasted conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) 50 mg enteric-coated tablet
Number of subjects: 24
Study: 24594247

Group type: EXPERIMENTAL
Intervention: Semi-recumbent positioning
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (Supine position)
Number of subjects: 34
Study: 22929268

Group type: EXPERIMENTAL
Intervention: Severe metopic synostosis (endocranial bifrontal angle 100 to 124 degrees)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Moderate metopic synostosis (endocranial bifrontal angle 124 to 148 degrees)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (endocranial bifrontal angle 134 to 160 degrees)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Severe metopic synostosis
Number of subjects: 35
Study: 20339875

Group type: EXPERIMENTAL
Intervention: Anatomical closure of trocar site using tip hole needle and redirecting suture hook
Number of subjects: 120
Study: 18442879

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral risperidone
Number of subjects: 50
Study: 16163920

Group type: EXPERIMENTAL
Intervention: Group SUP (supine position)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group LAT (lateral decubitus position)
Number of subjects: 26
Study: 12673167

Group type: EXPERIMENTAL
Intervention: Selective instillation of 131I-Lipiodol to the proper hepatic artery (SEL group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hyperselective instillation of 131I-Lipiodol in the right or left hepatic artery (HYP-SEL group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (SEL and HYP-SEL)
Number of subjects: 24
Study: 10545552

Group type: EXPERIMENTAL
Intervention: iNO at 2 ppm
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: iNO at 20 ppm (after initial treatment with 0 ppm)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: iNO at 20 ppm (after initial treatment with 2 ppm)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (0 ppm)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose iNO group (2 ppm)
Number of subjects: 38
Study: 8340472

Group type: EXPERIMENTAL
Intervention: Massage therapy (3 daily 15-minute massages for 10 days)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 93
Study: 3724994

Group type: EXPERIMENTAL
Intervention: Electrical shocks administered to the right forearm at four intensities
Number of subjects: 44
Study: 29850955

Group type: EXPERIMENTAL
Intervention: 1-cm surgical margin
Number of subjects: 400

Group type: COMPARATOR
Intervention: 2-cm surgical margin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study: 27894336

Group type: EXPERIMENTAL
Intervention: Curcumin alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Curcumin and long-chain omega-3 polyunsaturated fatty acids (double active)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 80
Study: 23891072

Group type: EXPERIMENTAL
Intervention: Lipid-lowering medications (LLM) at discharge
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Not discharged on lipid-lowering medications (LLM)
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Achieving LDL target level of <100 mg/dL
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Not achieving LDL target level of <100 mg/dL
Number of subjects: 2203
Study: 21192262

Group type: EXPERIMENTAL
Intervention: Immunotherapy (specific agents not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immune checkpoint inhibitors (specific agents not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer vaccines (specific formulations not detailed)
Number of subjects: 0
Study: 19333170

Group type: EXPERIMENTAL
Intervention: Bilateral transforaminal epidural steroid injections (TF ESIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injections (IL ESIs)
Number of subjects: 0
Study: 17556631

Group type: EXPERIMENTAL
Intervention: Standard intervention (handwashing program)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Expanded intervention (handwashing program, soap for school sinks, and peer hygiene monitors)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual practices (control)
Number of subjects: 87
Study: 15383106

Group type: EXPERIMENTAL
Intervention: Pregnant women at high altitude
Number of subjects: 175

Group type: COMPARATOR
Intervention: Pregnant women at sea level
Number of subjects: 175
Study: 11437986

Group type: EXPERIMENTAL
Intervention: Synthetic xenin at a dose of 4 pmol kg‐1 min‐1 infused for 10 min intravenously
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9085303

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Tramadol 150 mg
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg plus Codeine 60 mg
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg plus Propoxyphene 100 mg
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Tramadol (all doses)
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg and 100 mg
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Tramadol (higher doses)
Number of subjects: 3453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3453
Study: 7679166

Group type: EXPERIMENTAL
Intervention: Isradipine (ISR) 2.5 mg b.i.d. for 4 weeks
Number of subjects: 1647

Group type: EXPERIMENTAL
Intervention: Combination therapies (bopindolol, metolazone, enalapril, ISR 5 mg b.i.d.)
Number of subjects: 1647

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1647

Group type: EXPERIMENTAL
Intervention: ISR plus diuretics
Number of subjects: 1647

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (enalapril)
Number of subjects: 1647
Study: 3113538

Group type: EXPERIMENTAL
Intervention: Antibiotics given to patients with proved bacteriuria (80 patients)
Number of subjects: 4470

Group type: COMPARATOR
Intervention: No treatment (8 untreated patients with bacteriuria)
Number of subjects: 4470

Group type: COMPARATOR
Intervention: Unconfirmed bacteriuria (110 patients)
Number of subjects: 4470

Group type: COMPARATOR
Intervention: Non-bacteriuric controls (226 patients)
Number of subjects: 4470

Group type: EXPERIMENTAL
Intervention: Confirmed bacteriuria (226 patients)
Number of subjects: 4470

Group type: EXPERIMENTAL
Intervention: Screening and treatment program
Number of subjects: 4470
Study: 31758325

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 276
Study: 28812196

Group type: COMPARATOR
Intervention: FLS training
Number of subjects: 18

Group type: COMPARATOR
Intervention: VBLaST training
Number of subjects: 18
Study: 26460221

Group type: EXPERIMENTAL
Intervention: Nutritional nursing interventions (not specified in detail)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Regular weighing
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of risk factors
Number of subjects: 878
Study: 24643905

Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg weekly for 2 years
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 23091195

Group type: EXPERIMENTAL
Intervention: Metronidazole (MZ)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 25
Study: 19941679

Group type: EXPERIMENTAL
Intervention: 5 ml bittern containing 500 mg of Mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: 30 g butter with no Mg supplementation (fat-only meal)
Number of subjects: 16
Study: 18854289

Group type: EXPERIMENTAL
Intervention: Bortezomib/Dexamethasone (VD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib/Lenalidomide/Dexamethasone (VRD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control: Bortezomib/Dexamethasone (VD)
Number of subjects: 0
Study: 17085380

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol and 2 mg dienogest (E2/dienogest)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no menopausal therapy)
Number of subjects: 158
Study: 12660934

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (canarypox vector containing HIV-1 clade B antigens)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control vector (rabies virus glycoprotein G gene)
Number of subjects: 40
Study: 10823400

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (tea or coffee)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (75 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tea (75 mg caffeine)
Number of subjects: 30